Efficacy of Cyclophosphamide treatment for immunoglobulin G4-related disease with addition of glucocorticoids
Abstract Aim to evaluate the efficacy and safety of glucocorticoid monotherapy vs combination therapy of cyclophosphamide (CYC) for IgG4 related disease (IgG4-RD). 102 newly diagnosed IgG4-RD patients were enrolled and assigned to 2 groups: Group I was prednisone monotherapy (0.5–1.0 mg/kg.d, tapere...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2017
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/83c61c76b7ef4b1188ab78cd4c66d2ae |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:83c61c76b7ef4b1188ab78cd4c66d2ae |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:83c61c76b7ef4b1188ab78cd4c66d2ae2021-12-02T11:52:25ZEfficacy of Cyclophosphamide treatment for immunoglobulin G4-related disease with addition of glucocorticoids10.1038/s41598-017-06520-52045-2322https://doaj.org/article/83c61c76b7ef4b1188ab78cd4c66d2ae2017-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-06520-5https://doaj.org/toc/2045-2322Abstract Aim to evaluate the efficacy and safety of glucocorticoid monotherapy vs combination therapy of cyclophosphamide (CYC) for IgG4 related disease (IgG4-RD). 102 newly diagnosed IgG4-RD patients were enrolled and assigned to 2 groups: Group I was prednisone monotherapy (0.5–1.0 mg/kg.d, tapered gradually) and Group II was glucocorticoid and CYC (50–100 mg per day). Patients were assessed at different periods. Primary end point was relapse rate; secondary end points included response, remission rate and adverse effects. 52 patients were in Group I and 50 in Group II. At 1 month, both groups achieved obvious improvement. Accumulated relapse rate during 1 year was 38.5% in Group 1, including 12 cases with clinical relapse and 8 patients manifesting only serological relapse; whereas there was 12.0% of relapse in Group 2, only 1 with clinical relapse and other 5 patients got serological relapse. The mean flare time in Group II was significantly longer than that in Group I. All relapsing patients in Group I were sensitive to immunosuppressants. Most patients involving more than 6 organs in Group I relapsed during 1 year. IgG4 levels of relapse cases were significantly higher than non-relapsing patients at baseline. Bile duct, lacrimal glands and lymph nodes were commonly relapsed organs in Group I.Fei YunyunChen YuZhang PanpanChen HuaWu DiZhao LidanPeng LinyiWang LiWu QingjunZhang XuanZhao YanZeng XiaofengZhang FengchunZhang WenNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-8 (2017) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Fei Yunyun Chen Yu Zhang Panpan Chen Hua Wu Di Zhao Lidan Peng Linyi Wang Li Wu Qingjun Zhang Xuan Zhao Yan Zeng Xiaofeng Zhang Fengchun Zhang Wen Efficacy of Cyclophosphamide treatment for immunoglobulin G4-related disease with addition of glucocorticoids |
| description |
Abstract Aim to evaluate the efficacy and safety of glucocorticoid monotherapy vs combination therapy of cyclophosphamide (CYC) for IgG4 related disease (IgG4-RD). 102 newly diagnosed IgG4-RD patients were enrolled and assigned to 2 groups: Group I was prednisone monotherapy (0.5–1.0 mg/kg.d, tapered gradually) and Group II was glucocorticoid and CYC (50–100 mg per day). Patients were assessed at different periods. Primary end point was relapse rate; secondary end points included response, remission rate and adverse effects. 52 patients were in Group I and 50 in Group II. At 1 month, both groups achieved obvious improvement. Accumulated relapse rate during 1 year was 38.5% in Group 1, including 12 cases with clinical relapse and 8 patients manifesting only serological relapse; whereas there was 12.0% of relapse in Group 2, only 1 with clinical relapse and other 5 patients got serological relapse. The mean flare time in Group II was significantly longer than that in Group I. All relapsing patients in Group I were sensitive to immunosuppressants. Most patients involving more than 6 organs in Group I relapsed during 1 year. IgG4 levels of relapse cases were significantly higher than non-relapsing patients at baseline. Bile duct, lacrimal glands and lymph nodes were commonly relapsed organs in Group I. |
| format |
article |
| author |
Fei Yunyun Chen Yu Zhang Panpan Chen Hua Wu Di Zhao Lidan Peng Linyi Wang Li Wu Qingjun Zhang Xuan Zhao Yan Zeng Xiaofeng Zhang Fengchun Zhang Wen |
| author_facet |
Fei Yunyun Chen Yu Zhang Panpan Chen Hua Wu Di Zhao Lidan Peng Linyi Wang Li Wu Qingjun Zhang Xuan Zhao Yan Zeng Xiaofeng Zhang Fengchun Zhang Wen |
| author_sort |
Fei Yunyun |
| title |
Efficacy of Cyclophosphamide treatment for immunoglobulin G4-related disease with addition of glucocorticoids |
| title_short |
Efficacy of Cyclophosphamide treatment for immunoglobulin G4-related disease with addition of glucocorticoids |
| title_full |
Efficacy of Cyclophosphamide treatment for immunoglobulin G4-related disease with addition of glucocorticoids |
| title_fullStr |
Efficacy of Cyclophosphamide treatment for immunoglobulin G4-related disease with addition of glucocorticoids |
| title_full_unstemmed |
Efficacy of Cyclophosphamide treatment for immunoglobulin G4-related disease with addition of glucocorticoids |
| title_sort |
efficacy of cyclophosphamide treatment for immunoglobulin g4-related disease with addition of glucocorticoids |
| publisher |
Nature Portfolio |
| publishDate |
2017 |
| url |
https://doaj.org/article/83c61c76b7ef4b1188ab78cd4c66d2ae |
| work_keys_str_mv |
AT feiyunyun efficacyofcyclophosphamidetreatmentforimmunoglobuling4relateddiseasewithadditionofglucocorticoids AT chenyu efficacyofcyclophosphamidetreatmentforimmunoglobuling4relateddiseasewithadditionofglucocorticoids AT zhangpanpan efficacyofcyclophosphamidetreatmentforimmunoglobuling4relateddiseasewithadditionofglucocorticoids AT chenhua efficacyofcyclophosphamidetreatmentforimmunoglobuling4relateddiseasewithadditionofglucocorticoids AT wudi efficacyofcyclophosphamidetreatmentforimmunoglobuling4relateddiseasewithadditionofglucocorticoids AT zhaolidan efficacyofcyclophosphamidetreatmentforimmunoglobuling4relateddiseasewithadditionofglucocorticoids AT penglinyi efficacyofcyclophosphamidetreatmentforimmunoglobuling4relateddiseasewithadditionofglucocorticoids AT wangli efficacyofcyclophosphamidetreatmentforimmunoglobuling4relateddiseasewithadditionofglucocorticoids AT wuqingjun efficacyofcyclophosphamidetreatmentforimmunoglobuling4relateddiseasewithadditionofglucocorticoids AT zhangxuan efficacyofcyclophosphamidetreatmentforimmunoglobuling4relateddiseasewithadditionofglucocorticoids AT zhaoyan efficacyofcyclophosphamidetreatmentforimmunoglobuling4relateddiseasewithadditionofglucocorticoids AT zengxiaofeng efficacyofcyclophosphamidetreatmentforimmunoglobuling4relateddiseasewithadditionofglucocorticoids AT zhangfengchun efficacyofcyclophosphamidetreatmentforimmunoglobuling4relateddiseasewithadditionofglucocorticoids AT zhangwen efficacyofcyclophosphamidetreatmentforimmunoglobuling4relateddiseasewithadditionofglucocorticoids |
| _version_ |
1718395055344975872 |